Lilly strengthens neuroscience portfolio with Centessa acquisition
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
Eli Lilly announced the closing of the acquisition of Centesse Pharmaceuticals plc, an operation with which he strengthens his portfolio in neuroscience and accelerates his commitment to treatments for narcolepsy and other sleep-vigilial disorders based on orexin receptor agonists 2. *** Eli Lilly confirmed the completion of the purchase of Centesse Pharmaceuticals plc. The biotechnology develops orexin 2 receptor agonists to treat narcolepsy an…
Eli Lilly Completes Acquisition of Centessa Pharmaceuticals to Advance Narcolepsy Treatments
The acquisition adds Centessa’s clinical-stage orexin receptor 2 agonists to Lilly’s pipeline, targeting narcolepsy and other sleep-wake disorders. Key takeaways: Eli Lilly and Company has successfully acquired clinical-stage company Centessa Pharmaceuticals. The acquisition focuses on advancing the development of orexin receptor 2 agonists. These medicines are being developed to treat narcolepsy and potentially other sleep-wake disorders. Eli …
Lilly strengthens neuroscience portfolio with Centessa acquisition
INDIANAPOLIS – Eli Lilly and Company has completed its acquisition of Centessa Pharmaceuticals, strengthening the drugmaker’s neuroscience pipeline and broadening its efforts to develop new treatments for narcolepsy and other sleep-wake disorders.Centessa is developing orexin receptor 2 agonists, an emerging class of medicines that target the orexin system, which plays a critical role in regulating wakefulness, alertness and sleep stability. Lil…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
